News

To address the risk of bioterrorism, the US Food and Drug Administration has approved a drug for the treatment of smallpox, an acute contagious viral disease that was declared eradicated in 1980, but could still be reintroduced into

An international research group has reported promising data from an early clinical trial of a prophylactic vaccine against HIV-1 in healthy volunteers and a parallel study of the same vaccine in rhesus monkeys.

Forbion Capital Partners of the Netherlands has raised €270 million at the first close of its fourth life science fund, exceeding the target amount of €250 million.

The Wellcome Trust is to use its expertise in life science and financial muscle to launch a new investment fund that will enable high-risk research projects to develop quickly and move towards commercialisation.

London, UK-based Abingworth has raised $315 million for its twelfth life science fund bringing the total amount of funds under management to over $1.2 billion.

A prospective drug for Alzheimer’s disease that failed to show efficacy in late 2017 based on a Bayesian analysis of patient data, has now demonstrated its promise using more conventional statistical methods, according to Eisai Co L

A consortium of predominately European investors is providing €47 million to Dynacure SAS of France to bring its candidate antisense oligonucleotide drug into the clinic for the treatment of patients with centronuclear myopathies.

Ipsen SA received further validation of its in-licensed compound cabozantinib following the publication in the 5 July edition of the New England Journal of Medicine (NEJM) of Phase 3 data showing the drug’s effectiveness in advanced liver cancer.

Deborah Dunsire, an experienced pharmaceutical company chief executive, is set to become CEO of H. Lundbeck A/S on 1 September.

A candidate vaccine to prevent infection from the chikungunya virus has been accepted into the European Medicines Agency’s PRIME scheme, a programme of regulatory support for developers of medicines that meet a major public health n